COMPANY

QuantX Biosciences

Keywords: small molecule immunology psoriasis Atopic Dermatitis QX4533 QX-4533

Location: Princeton, NJ · source · Oct 14, 2026

Profile checked Oct 10, 2026

Timeline

Sep 14, 2026 Trial start 1: Phase 1 Study of QX-4533 in Healthy Volunteers and Patients With Moderate-to-Severe Atopic Dermatitis source ↗
Jul 10, 2026 Trial start Phase 1: A Single and Multiple Ascending Dose Escalation and Food Effect Study of QX-4533 in Healthy Participants source ↗

Dec 25, 2026 (ESTIMATED) · Phase 1 · A Single and Multiple Ascending Dose Escalation and Food Effect Study of QX-4533 in Healthy Participants · NCT07678463
Apr 14, 2027 (ESTIMATED) · 1 · Phase 1 Study of QX-4533 in Healthy Volunteers and Patients With Moderate-to-Severe Atopic Dermatitis · NCT07800104

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT07800104	Phase 1 Study of QX-4533 in Healthy Volunteers and Patients With Moderate-to-Severe Atopic Dermatitis	1	Recruiting	Sep 14, 2026	Apr 14, 2027 (estimated)
NCT07678463	A Single and Multiple Ascending Dose Escalation and Food Effect Study of QX-4533 in Healthy Participants	Phase 1	Recruiting	Jul 10, 2026	Dec 25, 2026 (estimated)

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of OrbiMed (captured Oct 12, 2026). portfolio page ↗

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-04